FDA's Clinical Hold Doesn't Affect Magenta Therapeutics' (MGTA) MGTA-117 Prospects - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Magenta Therapeutics (MGTA) PT Lowered to $20 at Wedbush, Following Clinical Business Update
July 21, 2021 9:59 AM EDTWedbush analyst David Nierengarten lowered the price target on Magenta Therapeutics (NASDAQ: MGTA) to $20.00 (from $22.00) while maintaining a Outperform rating.
... MorePre-Open Stock Movers 07/21: (CEMI) (LE) (SDC) Higher; (SNBR) (FOUR) (MGTA) Lower (more...)
July 21, 2021 9:20 AM EDTPre-Open Stock Movers
Chembio Diagnostics, Inc. (Nasdaq: CEMI) 92.7% HIGHER; announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembios DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazils Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is designed to detect the SARS-CoV-2 antigen, which indicates an active COVID-19 infection, in only 20 minutes using a... More
Magenta Therapeutics (MGTA) to Resume Trading at 8:30 a.m.
July 21, 2021 8:08 AM EDTMagenta Therapeutics (NASDAQ: MGTA) to Resume Trading at 8:30 a.m.
... MoreMagenta Therapeutics (MGTA) receives clinical hold letter from FDA related to IND to initiate Phase 1/2 clinical trial of MGTA-117 in patients with AML and MDS
July 21, 2021 8:01 AM EDTMagenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The FDA is requiring that Magenta develop an additional bioassay to be used in conjunction with the PK/PD model to inform dose escalation decisions in addition to safety monitoring. This was the only clinical... More
Magenta Therapeutics (MGTA) Halted, News Pending
July 21, 2021 7:55 AM EDTMagenta Therapeutics (NASDAQ: MGTA) Halted, News Pending
... More